Drug Trial News

RSS

Isis receives $4 million in milestone payment from Achaogen for initiation of plazomicin Phase 3 study

Isis Pharmaceuticals, Inc. announced that it has earned a $4 million milestone payment from Achaogen, Inc. associated with the initiation of a Phase 3 study of plazomicin in patients with serious multi-drug resistant (MDR), gram-negative bacterial infections.

17 Sep 2014

Radiation and endocrine therapy combination may not be necessary for all HR+ breast cancer patients

Treatment with endocrine therapy and radiation therapy as part of breast conservation is the current standard of care for women with hormone-receptor positive (HR+) invasive breast cancer. A new study by researchers at Fox Chase Cancer Center, however, shows that combination may not be necessary for all patient populations with the disease.

17 Sep 2014

UCSD researchers launch phase 1 trial to assess novel monoclonal antibody for CLL patients

Researchers at the University of California, San Diego School of Medicine have launched a phase 1 human clinical trial to assess the safety and efficacy of a new monoclonal antibody for patients with chronic lymphocytic leukemia (CLL), the most common form of blood cancer in adults.

17 Sep 2014

Cancer-fighting cocktail shows promising results for advanced cervical cancer

Combining a standard chemotherapy drug with a second drug that stops cells from dividing improves both the survival and response rates for those with advanced cervical cancer, a new study by UT Southwestern Medical Center cancer researchers finds.

16 Sep 2014

Bayer, Orion begin patient enrollment in ODM-201 Phase III trial for castration-resistant prostate cancer

Bayer HealthCare and Orion Corporation, a pharmaceutical company based in Espoo, Finland, have begun to enroll patients in a Phase III trial with ODM-201, an investigational oral androgen receptor inhibitor in clinical development.

16 Sep 2014

Amgen announces phase 3 ivabradine data for treatment of chronic HF

Amgen (NASDAQ: AMGN) today announced data from the Phase 3 SHIFT (Systolic Heart failure treatment with the If inhibitor ivabradine Trial) study evaluating ivabradine in patients with chronic heart failure (HF) were presented at the 18th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) in Las Vegas.

15 Sep 2014

Ramucirumab Phase III study meets primary endpoint in patients with metastatic colorectal cancer

Eli Lilly and Company today announced that the RAISE trial, a Phase III study of ramucirumab (CYRAMZA) in combination with chemotherapy in patients with metastatic colorectal cancer (mCRC), met its primary endpoint of overall survival.

15 Sep 2014

AbbVie’s Phase 3 pivotal study shows HUMIRA is effective in reducing symptoms in HS

AbbVie today announced results from a Phase 3 pivotal study demonstrating that HUMIRA® (adalimumab) is effective in reducing common clinical signs and symptoms in moderate-to-severe hidradenitis suppurativa (HS), specifically the number of abscesses and inflammatory nodules.

11 Sep 2014

Experimental vaccine protects monkeys exposed to Ebola virus

One shot of an experimental vaccine made from two Ebola virus gene segments incorporated into a chimpanzee cold virus vector (called chimp adenovirus type 3 or ChAd3) protected all four macaque monkeys exposed to high levels of Ebola virus 5 weeks after inoculation, report National Institutes of Health (NIH) scientists and their collaborators.

9 Sep 2014

Mayo Clinic and IBM plan to pilot Watson to begin research studies in cancer

Mayo Clinic and IBM today announced plans to pilot Watson, the IBM cognitive computer, to match patients more quickly with appropriate clinical trials, beginning with research studies in cancer. A proof-of-concept phase is currently underway.

9 Sep 2014

Agents targeting mitochondrial metabolism can have activity in leukemia

Results of a Phase I clinical trial showed that a new drug targeting mitochondrial function in human cancer cells was safe and showed some efficacy.

9 Sep 2014

New data from Boehringer's Phase III trial program evaluates efficacy of tiotropium in asthma patients

Boehringer Ingelheim today presented new data from the company's Phase III trial program (UniTinA-asthma®) evaluating tiotropium in asthma, including the first study assessing the efficacy and safety of tiotropium in adolescent patients with symptomatic asthma.

9 Sep 2014

Soligenix acquires novel orphan drug candidate for treatment of CTCL

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today the acquisition of a novel orphan drug candidate, known as SGX301 (synthetic hypericin).

8 Sep 2014

Peramivir drug safe, effective at alleviating influenza symptoms

An analysis of phase 2 and phase 3 clinical trials shows that a single injected dose of the neuraminidase inhibitor (NAI) peramivir is safe and effective at alleviating influenza symptoms, including fever and viral shedding, when administered within 48 hours of the onset of symptoms.

6 Sep 2014

Researchers to study effectiveness of atorvastatin in preventing heart problems in breast cancer patients

Wake Forest Baptist Medical Center has been awarded $4.4 million to conduct a multiple-site clinical trial testing the effectiveness of a statin drug in preventing cardiovascular events in women treated for breast cancer.

5 Sep 2014

Oncolytics Biotech completes randomized Phase 2 study of ovarian, fallopian tube cancer

Oncolytics Biotech Inc. today announced that patient enrollment has been completed in a randomized Phase 2 study of paclitaxel plus REOLYSIN® versus paclitaxel alone in patients with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer (GOG186H).

4 Sep 2014

Drug Trial News

Isis receives $4 million in milestone payment from Achaogen for initiation of plazomicin Phase 3 study

Radiation and endocrine therapy combination may not be necessary for all HR+ breast cancer patients

UCSD researchers launch phase 1 trial to assess novel monoclonal antibody for CLL patients

Cancer-fighting cocktail shows promising results for advanced cervical cancer

Bayer, Orion begin patient enrollment in ODM-201 Phase III trial for castration-resistant prostate cancer

Amgen announces phase 3 ivabradine data for treatment of chronic HF

Ramucirumab Phase III study meets primary endpoint in patients with metastatic colorectal cancer

AbbVie’s Phase 3 pivotal study shows HUMIRA is effective in reducing symptoms in HS

Experimental vaccine protects monkeys exposed to Ebola virus

Mayo Clinic and IBM plan to pilot Watson to begin research studies in cancer

Agents targeting mitochondrial metabolism can have activity in leukemia

New data from Boehringer's Phase III trial program evaluates efficacy of tiotropium in asthma patients

Soligenix acquires novel orphan drug candidate for treatment of CTCL

Peramivir drug safe, effective at alleviating influenza symptoms

Researchers to study effectiveness of atorvastatin in preventing heart problems in breast cancer patients

Oncolytics Biotech completes randomized Phase 2 study of ovarian, fallopian tube cancer

Ascend Biopharmaceuticals provides update on clinical trial program for lead immunotherapy products

Novira completes Phase 1a clinical study of NVR-1221 for treatment of HBV infection

Positive clinical data for first procedural therapy to treat type 2 diabetes from Fractyl

F2G begins F901318 Phase I clinical study for treatment of aspergillus infections

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News